Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FRA:F9L's PB Ratio is ranked better than 70% of 920
companies
in the Drug Manufacturers industry
Industry Median: 1.99
vs FRA:F9L: 1.21
During the past 12 months, Joincare Pharmaceutical Group Industry Co's average Book Value Per Share Growth Rate was 6.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 6.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 7.90% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 11.30% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Joincare Pharmaceutical Group Industry Co was 89.20% per year. The lowest was -0.50% per year. And the median was 9.10% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Joincare Pharmaceutical Group Industry Co PB Ratio Related Terms
Joincare Pharmaceutical Group Industry Co PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Joincare Pharmaceutical Group Industry Co PB Ratio Chart
Joincare Pharmaceutical Group Industry Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Joincare Pharmaceutical Group Industry Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Joincare Pharmaceutical Group Industry Co PB Ratio vs Drug Manufacturers Industry
Joincare Pharmaceutical Group Industry Co PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Joincare Pharmaceutical Group Industry Co (FRA:F9L) has a PB Ratio of 0.62 as of Aug. 13, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Joincare Pharmaceutical Group Industry Co and its competitors. This is 67% below median its historical median of 1.87. Over the past decade, Joincare Pharmaceutical Group Industry Co's PB Ratio has ranged from 1.09 to 3.77. According to the industry distribution chart, Joincare Pharmaceutical Group Industry Co ranks #276 out of 920 companies in the Drug Manufacturers industry, placing it in the top 30%.
Is Joincare Pharmaceutical Group Industry Co's PB Ratio too high?
Joincare Pharmaceutical Group Industry Co's current PB Ratio of 0.62 is 67% below median its 10-year median of 1.87. Over the past 10 years, this metric has ranged from a low of 1.09 to a high of 3.77. The Drug Manufacturers industry median PB Ratio is 1.99. Joincare Pharmaceutical Group Industry Co's value of 0.62 is 68.8% below this industry median. Based on the distribution chart, Joincare Pharmaceutical Group Industry Co ranks #276 out of 920 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Joincare Pharmaceutical Group Industry Co has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Joincare Pharmaceutical Group Industry Co's PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Joincare Pharmaceutical Group Industry Co ranks #276 out of 920 companies for PB Ratio. This puts Joincare Pharmaceutical Group Industry Co in the upper half of its industry. The industry median PB Ratio is 1.99. Joincare Pharmaceutical Group Industry Co's value of 0.62 is 68.8% below this benchmark. Historically, Joincare Pharmaceutical Group Industry Co's own PB Ratio has ranged from 1.09 to 3.77 over the past decade. While the company's 10-year median is 1.87 vs. the industry median of 1.99, Joincare Pharmaceutical Group Industry Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.99, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Joincare Pharmaceutical Group Industry Co's current PB Ratio of 0.62 is 68.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Joincare Pharmaceutical Group Industry Co and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Joincare Pharmaceutical Group Industry Co's current PB Ratio is 0.62, which is 67% below median its own 10-year median of 1.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Joincare Pharmaceutical Group Industry Co stock overvalued right now?
Joincare Pharmaceutical Group Industry Co (FRA:F9L) has a current PB Ratio of 0.62. The stock's GF Value™ is €7.53, compared to a current price of €6.60 — trading 12.4% below its estimated fair value. The current PB Ratio is 0.62, which is 67% below median its 10-year median of 1.87 and 68.8% below the Drug Manufacturers industry median of 1.99. Joincare Pharmaceutical Group Industry Co's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Joincare Pharmaceutical Group Industry Co (FRA:F9L), the current PB Ratio is 0.62 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Joincare Pharmaceutical Group Industry Co (FRA:F9L) Overvalued in 2026?
Based on GuruFocus' analysis, Joincare Pharmaceutical Group Industry Co stock appears to be undervalued.
The current stock price of €6.60 is trading 12.4% below its estimated GF Value™ of €7.53.
Key valuation signals for FRA:F9L:
PB Ratio: 0.62 (67% below median its 10-year median of 1.87)
GF Value™: €7.53 vs. price of €6.60 (12.4% below fair value)
Industry Position: 68.8% below the Drug Manufacturers median (#276 of 920)
No single metric tells the full story. See the FRA:F9L stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Joincare Pharmaceutical Group Industry Co Ltd is an integrated pharmaceutical company, the business scope covers healthcare products, APIs, final dosage forms, prescription drugs, OTCs, Chinese traditional medicine, chemical drugs, and testing agents. APIs are antibiotic series and their intermediates 7ACA, 4AA and F9. Prescription drugs focus on the realms of the digestive tract, a blood vessel of heart and brain, infection, tumor, nervous cerebrovascular section, urinary system etc. OTCs include gastrointestinal drug Dele-Livzon, Live Bifidobacterium Preparation, oral ulcer drugs Yiketie, cold medicine Antiviral Oral Granule, External use skin medicine.
80GF Score
Get the complete analysis for FRA:F9L
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:F9L has been successfully added to your 
